Eris Lifesciences's Total Assets for the quarter that ended in Mar. 2026 was ₹73,655 Mil.
Warning Sign:
If a company builds assets at 37.8% a year, faster than its revenue growth rate of 23.1% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Eris Lifesciences's average Total Assets Growth Rate was 6.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 26.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 37.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 33.10% per year.
During the past 13 years, Eris Lifesciences's highest 3-Year average Total Assets Growth Rate was 68.70%. The lowest was 8.70%. And the median was 41.90%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Eris Lifesciences's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Eris Lifesciences Total Assets Related Terms
Eris Lifesciences Total Assets Historical Data
* Premium members only.
The historical data trend for Eris Lifesciences's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Eris Lifesciences's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eris Lifesciences (BOM:540596) has a Total Assets of ₹73,655 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Eris Lifesciences and its competitors.
Is Eris Lifesciences' Total Assets too high?
Eris Lifesciences' current Total Assets is ₹73,655 Mil. Overall, Eris Lifesciences has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' Total Assets compare to ZTS and UTHR?
Eris Lifesciences' Total Assets of ₹73,655 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Eris Lifesciences and its competitors. Eris Lifesciences's current Total Assets is ₹73,655 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (BOM:540596) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,652.66, compared to a current price of ₹1,428.70 — trading 13.6% below its estimated fair value. The current Total Assets is ₹73,655 Mil. Eris Lifesciences' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Eris Lifesciences (BOM:540596), the current Total Assets is ₹73,655 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (BOM:540596) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,428.70 is trading 13.6% below its estimated GF Value™ of ₹1,652.66.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for BOM:540596:
Total Assets: ₹73,655 Mil
GF Value™: ₹1,652.66 vs. price of ₹1,428.70 (13.6% below fair value)
No single metric tells the full story. See the BOM:540596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
93GF Score
Get the complete analysis for BOM:540596
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540596 has been successfully added to your 
